Current Treatment Options in Oncology

, Volume 12, Issue 4, pp 354–368 | Cite as

The 5q- Syndrome: Biology and Treatment

Leukemia (Janice Dutcher, Section Editor)

Opinion statement

The 5q- syndrome is a myelodsyplastic syndrome (MDS) characterized by symptomatic anemia and an indolent natural history with low transformation potential. Our understanding of the molecular pathogenesis of this disease has advanced considerably, paralleled by the delineation of the relevant targets underlying selective lenalidomide sensitivity. The context in which one treats the 5q- syndrome, and all lower risk MDS, is critical. The focus of treatment should remain the amelioration of refractory cytopenias. In the 5q- syndrome, lenalidomide is the treatment of choice for patients with symptomatic anemia as it relieves the burden of transfusion dependence and iron overload in the majority of cases. We discuss herein the current understanding of the biology of the 5q- syndrome, actions of efficacy of lenalidomide and strategies for clinical management.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: •Of importance ••Of major importance

  1. 1.
    Van Den Berghe H, Cassiman J-J, David G, Fryns J-P, Michaux J-L, Sokal G. Distinct haematological disorder with deletion of long arm of No. 5 chromosome. Nature. 1974;251:437–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Nimer SD, Golde DW. The 5q- abnormality. Blood. 1987;70:1705–12.PubMedGoogle Scholar
  3. 3.
    Mohamedali A, Mufti GJ. Van-den Berghe's 5q- syndrome in 2008. Br J Haematol. 2009;144:157–68.PubMedCrossRefGoogle Scholar
  4. 4.
    Nimer SD. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q. J Clin Oncol. 2006;24:2576–82.PubMedCrossRefGoogle Scholar
  5. 5.
    Komrokji RS, List AF. Lenalidomide for treatment of myelodysplastic syndromes: current status and future directions. Hematol Oncol Clin North Am. 2010;24:377–88.PubMedCrossRefGoogle Scholar
  6. 6.
    List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005;352:549–57.PubMedCrossRefGoogle Scholar
  7. 7.
    Kantarjian H, O'Brien S, Ravandi F, et al. The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS? Cancer. 2009;115:5202–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Zhao N, Stoffel A, Wang PW, et al. Molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases to 1–1.5 Mb and preparation of a PAC-based physical map. Proc Natl Acad Sci U S A. 1997;94:6948–53.PubMedCrossRefGoogle Scholar
  9. 9.
    Jaju RJ, Boultwood J, Oliver FJ, et al. Molecular cytogenetic delineation of the critical deleted region in the 5q- syndrome. Genes Chromosomes Cancer. 1998;22:251–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Le Beau MM, Espinosa 3rd R, Neuman WL, et al. Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases. Proc Natl Acad Sci U S A. 1993;90:5484–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Boultwood J, Fidler C, Lewis S, et al. Molecular mapping of uncharacteristically small 5q deletions in two patients with the 5q- syndrome: delineation of the critical region on 5q and identification of a 5q- breakpoint. Genomics. 1994;19:425–32.PubMedCrossRefGoogle Scholar
  12. 12.
    Willman CL, Sever CE, Pallavicini MG, et al. Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia. Science. 1993;259:968–71.PubMedCrossRefGoogle Scholar
  13. 13.
    Boultwood J, Fidler C, Strickson AJ, et al. Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome. Blood. 2002;99:4638–41.PubMedCrossRefGoogle Scholar
  14. 14.
    Boultwood J, Pellagatti A, Cattan H, et al. Gene expression profiling of CD34+ cells in patients with the 5q- syndrome. Br J Haematol. 2007;139:578–89.PubMedCrossRefGoogle Scholar
  15. 15.
    Pellagatti A, Cazzola M, Giagounidis A, et al. Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells. Leukemia. 2010;24:756–64.PubMedCrossRefGoogle Scholar
  16. 16.
    Liu TX, Becker MW, Jelinek J, et al. Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation. Nat Med. 2007;13:78–83.PubMedCrossRefGoogle Scholar
  17. 17.
    Pellagatti A, Cazzola M, Giagounidis AA, et al. Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype. Blood. 2006;108:337–45.PubMedCrossRefGoogle Scholar
  18. 18.
    Ebert BL, Pretz J, Bosco J, et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature. 2008;451:335–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Nakamichi NN, Kao FT, Wasmuth J, Roufa DJ. Ribosomal protein gene sequences map to human chromosomes 5, 8, and 17. Somat Cell Mol Genet. 1986;12:225–36.PubMedCrossRefGoogle Scholar
  20. 20.
    Rhoads DD, Dixit A, Roufa DJ. Primary structure of human ribosomal protein S14 and the gene that encodes it. Mol Cell Biol. 1986;6:2774–83.PubMedGoogle Scholar
  21. 21.
    Dana S, Wasmuth JJ. Linkage of the leuS, emtB, and chr genes on chromosome 5 in humans and expression of human genes encoding protein synthetic components in human–Chinese hamster hybrids. Somatic Cell Genet. 1982;8:245–64.PubMedCrossRefGoogle Scholar
  22. 22.
    Narla A, Ebert BL. Ribosomopathies: human disorders of ribosome dysfunction. Blood. 2010;115:3196–205.PubMedCrossRefGoogle Scholar
  23. 23.
    Craven SE, French D, Ye W, de Sauvage F, Rosenthal A. Loss of Hspa9b in zebrafish recapitulates the ineffective hematopoiesis of the myelodysplastic syndrome. Blood. 2005;105:3528–34.PubMedCrossRefGoogle Scholar
  24. 24.
    McGowan KA, Li JZ, Park CY, et al. Ribosomal mutations cause p53-mediated dark skin and pleiotropic effects. Nat Genet. 2008;40:963–70.PubMedCrossRefGoogle Scholar
  25. 25.
    Heise C, Carter T, Schafer P, Chopra R. Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes. Expert Rev Anticancer Ther. 2010;10:1663–72.PubMedCrossRefGoogle Scholar
  26. 26.
    Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992;69:1237–45.PubMedCrossRefGoogle Scholar
  27. 27.
    Ferreira-Cerca S, Hurt E. Cell biology: arrest by ribosome. Nature. 2009;459:46–7.PubMedCrossRefGoogle Scholar
  28. 28.••
    Barlow JL, Drynan LF, Hewett DR, et al. A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome. Nat Med 2010;16:59–66. This manuscript successfully crossed a powerful mouse model of the 5q- syndrome with a p-53 deficient mouse strain. This cross resulted in restoration of the hematopoetic progenitor defects seen in the 5q- model suggesting a critical P53 dependent mechanism. Google Scholar
  29. 29.
    Jadersten M, Saft L, Smith A, et al. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol. 2011;29:1971–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Starczynowski DT, Karsan A. Deregulation of innate immune signaling in myelodysplastic syndromes is associated with deletion of chromosome arm 5q. Cell Cycle. 2010;9:855–6.PubMedCrossRefGoogle Scholar
  31. 31.•
    Starczynowski DT, Kuchenbauer F, Argiropoulos B, et al. Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat Med 2010;16:49–58. This mansucript identified two miRs expressed within the common deleted region and their targets. They further showed that knocking these miRs down resulted in the partial recapitulation of the 5q- syndrome phenotype in a murine model. Google Scholar
  32. 32.
    DeWard AD, Leali K, West RA, Prendergast GC, Alberts AS. Loss of RhoB expression enhances the myelodysplastic phenotype of mammalian diaphanous-related Formin mDia1 knockout mice. PLoS One. 2009;4:e7102.PubMedCrossRefGoogle Scholar
  33. 33.
    Eisenmann KM, Dykema KJ, Matheson SF, et al. 5q- myelodysplastic syndromes: chromosome 5q genes direct a tumor-suppression network sensing actin dynamics. Oncogene. 2009;28:3429–41.PubMedCrossRefGoogle Scholar
  34. 34.
    Peng J, Kitchen SM, West RA, Sigler R, Eisenmann KM, Alberts AS. Myeloproliferative defects following targeting of the Drf1 gene encoding the mammalian diaphanous related formin mDia1. Cancer Res. 2007;67:7565–71.PubMedCrossRefGoogle Scholar
  35. 35.
    Huang RP, Fan Y, de Belle I, et al. Decreased Egr-1 expression in human, mouse and rat mammary cells and tissues correlates with tumor formation. Int J Cancer. 1997;72:102–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Sukhatme VP, Cao XM, Chang LC, et al. A zinc finger-encoding gene coregulated with c-fos during growth and differentiation, and after cellular depolarization. Cell. 1988;53:37–43.PubMedCrossRefGoogle Scholar
  37. 37.
    Lemaire P, Revelant O, Bravo R, Charnay P. Two mouse genes encoding potential transcription factors with identical DNA-binding domains are activated by growth factors in cultured cells. Proc Natl Acad Sci U S A. 1988;85:4691–5.PubMedCrossRefGoogle Scholar
  38. 38.
    Liu C, Adamson E, Mercola D. Transcription factor EGR-1 suppresses the growth and transformation of human HT-1080 fibrosarcoma cells by induction of transforming growth factor beta 1. Proc Natl Acad Sci U S A. 1996;93:11831–6.PubMedCrossRefGoogle Scholar
  39. 39.
    Liu C, Yao J, de Belle I, Huang RP, Adamson E, Mercola D. The transcription factor EGR-1 suppresses transformation of human fibrosarcoma HT1080 cells by coordinated induction of transforming growth factor-beta1, fibronectin, and plasminogen activator inhibitor-1. J Biol Chem. 1999;274:4400–11.PubMedCrossRefGoogle Scholar
  40. 40.
    Virolle T, Krones-Herzig A, Baron V, De Gregorio G, Adamson ED, Mercola D. Egr1 promotes growth and survival of prostate cancer cells. Identification of novel Egr1 target genes. J Biol Chem. 2003;278:11802–10.PubMedCrossRefGoogle Scholar
  41. 41.
    Joslin JM, Fernald AA, Tennant TR, et al. Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders. Blood. 2007;110:719–26.PubMedCrossRefGoogle Scholar
  42. 42.
    Swaroop A, Hogan BL, Francke U. Molecular analysis of the cDNA for human SPARC/osteonectin/BM-40: sequence, expression, and localization of the gene to chromosome 5q31-q33. Genomics. 1988;2:37–47.PubMedCrossRefGoogle Scholar
  43. 43.
    Goldblum SE, Ding X, Funk SE, Sage EH. SPARC (secreted protein acidic and rich in cysteine) regulates endothelial cell shape and barrier function. Proc Natl Acad Sci U S A. 1994;91:3448–52.PubMedCrossRefGoogle Scholar
  44. 44.
    Pellagatti A, Jadersten M, Forsblom AM, et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci U S A. 2007;104:11406–11.PubMedCrossRefGoogle Scholar
  45. 45.
    Zhang L-H, Schafer PH, Muller G, Stirling D, Bartlett B. Direct inhibitory effects of lenalidomide on the proliferation and VEGF production of non-hodgkin lymphoma cells are associated with increased SPARC expression. Blood (ASH Annual Meeting Abstracts) 2008;112:2612-.Google Scholar
  46. 46.
    Lehmann S, O'Kelly J, Raynaud S, Funk SE, Sage EH, Koeffler HP. Common deleted genes in the 5q- syndrome: thrombocytopenia and reduced erythroid colony formation in SPARC null mice. Leukemia. 2007;21:1931–6.PubMedCrossRefGoogle Scholar
  47. 47.
    Fidler C, Strickson A, Boultwood J, Waincoat JS. Mutation analysis of the SPARC gene in the 5q-syndrome. Am J Hematol. 2000;64:324.PubMedCrossRefGoogle Scholar
  48. 48.
    Pokutta S, Weis WI. Structure of the dimerization and beta-catenin-binding region of alpha-catenin. Mol Cell. 2000;5:533–43.PubMedCrossRefGoogle Scholar
  49. 49.
    Vasioukhin V, Bauer C, Degenstein L, Wise B, Fuchs E. Hyperproliferation and defects in epithelial polarity upon conditional ablation of alpha-catenin in skin. Cell. 2001;104:605–17.PubMedCrossRefGoogle Scholar
  50. 50.
    Shibata H, Takano H, Ito M, et al. Alpha-catenin is essential in intestinal adenoma formation. Proc Natl Acad Sci U S A. 2007;104:18199–204.PubMedCrossRefGoogle Scholar
  51. 51.
    Gil-Bernabe AM, Romero F, Limon-Mortes MC, Tortolero M. Protein phosphatase 2A stabilizes human securin, whose phosphorylated forms are degraded via the SCF ubiquitin ligase. Mol Cell Biol. 2006;26:4017–27.PubMedCrossRefGoogle Scholar
  52. 52.
    Jones TA, Barker HM, da Cruz e Silva EF, et al. Localization of the genes encoding the catalytic subunits of protein phosphatase 2A to human chromosome bands 5q23-->q31 and 8p12-->p11.2, respectively. Cytogenet Cell Genet 1993;63:35–41.Google Scholar
  53. 53.••
    Wei S, Chen X, Rocha K, et al. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci U S A 2009;106:12974–9. This manuscript identifies a link between the common deleted region and sensitivity to lenalidomide in low risk MDS with a del(5q) abnormality. Google Scholar
  54. 54.
    Sartor H, Ehlert F, Grzeschik KH, Muller R, Adolph S. Assignment of two human cell cycle genes, CDC25C and CCNB1, to 5q31 and 5q12, respectively. Genomics. 1992;13:911–2.PubMedCrossRefGoogle Scholar
  55. 55.
    Strausfeld U, Labbe JC, Fesquet D, et al. Dephosphorylation and activation of a p34cdc2/cyclin B complex in vitro by human CDC25 protein. Nature. 1991;351:242–5.PubMedCrossRefGoogle Scholar
  56. 56.
    Gould KL, Moreno S, Tonks NK, Nurse P. Complementation of the mitotic activator, p80cdc25, by a human protein-tyrosine phosphatase. Science. 1990;250:1573–6.PubMedCrossRefGoogle Scholar
  57. 57.
    Bulavin DV, Higashimoto Y, Popoff IJ, et al. Initiation of a G2/M checkpoint after ultraviolet radiation requires p38 kinase. Nature. 2001;411:102–7.PubMedCrossRefGoogle Scholar
  58. 58.
    Ebert BL. Deletion 5q in myelodysplastic syndrome: a paradigm for the study of hemizygous deletions in cancer. Leukemia. 2009;23:1252–6.PubMedCrossRefGoogle Scholar
  59. 59.
    Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001;98:210–6.PubMedCrossRefGoogle Scholar
  60. 60.
    List AF, Baker AF, Green S, Bellamy W. Lenalidomide: targeted anemia therapy for myelodysplastic syndromes. Cancer Control. 2006;13(Suppl):4–11.PubMedGoogle Scholar
  61. 61.
    List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355:1456–65.PubMedCrossRefGoogle Scholar
  62. 62.
    List A, Wride K, Knight R. Transfusion burden, disease duration and age identify non-deletion 5q MDS patients highly responsive to lenalidomide treatment. European Hematology Association, 13th congress 2008.Google Scholar
  63. 63.
    Sekeres MA, Maciejewski JP, Giagounidis AA, et al. Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. J Clin Oncol. 2008;26:5943–9.PubMedCrossRefGoogle Scholar
  64. 64.
    Fenaux P, Giagounidis A, Selleslag DL, et al. Safety of lenalidomide (LEN) from a randomized phase III trial (MDS-004) in low-/int-1-risk myelodysplastic syndromes (MDS) with a del(5q) abnormality. J Clin Oncol (Meeting Abstracts) 2010;28:6598-.Google Scholar
  65. 65.•
    Fenaux P, Giagounidis A, Selleslag D, et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood 2011. This is a large phase 3 clinical trial preformed in Europe confirming the superior efficacy and acceptable safety of lenalidomide in low-risk transfusion dependent MDS patients with a del(5q) abnormality. Google Scholar
  66. 66.
    Ades L, Lebras F, Sebert M, et al. Risk of AML Evolution In Lower Risk MDS with Del 5q Treated with or without Lenalidomide. A Report by the Groupe Francophone Des Myelodysplasies (GFM). ASH Annual Meeting Abstracts 2010;116:976-.Google Scholar
  67. 67.
    Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer. 2004;4:314–22.PubMedCrossRefGoogle Scholar
  68. 68.
    Corral LG, Haslett PA, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol. 1999;163:380–6.PubMedGoogle Scholar
  69. 69.
    Escoubet-Lozach L, Lin IL, Jensen-Pergakes K, et al. Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res. 2009;69:7347–56.PubMedCrossRefGoogle Scholar
  70. 70.
    Muller GW, Chen R, Huang SY, et al. Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production. Bioorg Med Chem Lett. 1999;9:1625–30.PubMedCrossRefGoogle Scholar
  71. 71.
    Verhelle D, Corral LG, Wong K, et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res. 2007;67:746–55.PubMedCrossRefGoogle Scholar
  72. 72.
    List AF, Rocha K, Zhang L, et al. Secondary Resistance to Lenalidomide in Del(5q) MDS Is Associated with CDC25C & PP2A Overexpression. ASH Annual Meeting Abstracts 2009;114:292-.Google Scholar
  73. 73.••
    Tehranchi R, Woll PS, Anderson K, et al. Persistent malignant stem cells in del(5q) myelodysplasia in remission. N Engl J Med 2010;363:1025–37. Lenalidomide responding patients with the 5q- syndrome are not cured from their disease. Relapse is nearly universal after some time. This manuscript provides biological evidence of this by showing that, even in responding patient, there exists a lenalidomide non-responsive stem cell compartment Google Scholar
  74. 74.
    Coulthard LR, White DE, Jones DL, McDermott MF, Burchill SA. p38(MAPK): stress responses from molecular mechanisms to therapeutics. Trends Mol Med. 2009;15:369–79.PubMedCrossRefGoogle Scholar
  75. 75.
    Musto P, Maurillo L, Spagnoli A, et al. Azacitidine for the treatment of lower risk myelodysplastic syndromes: a retrospective study of 74 patients enrolled in an Italian named patient program. Cancer. 2010;116:1485–94.PubMedCrossRefGoogle Scholar
  76. 76.
    Zhang Y, Lu H. Signaling to p53: ribosomal proteins find their way. Cancer Cell. 2009;16:369–77.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Malignant Hematology DepartmentH. Lee Moffitt Cancer CenterTampaUSA
  2. 2.H. Lee Moffitt Cancer CenterTampaUSA

Personalised recommendations